Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 10, 2016, Pages 1773-1782

  Nguyen, Linh ^a   Ager, Eleanor I ^a   Neo, Jaclyn ^a   Christophi, Christopher ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

colorectal cancer; liver; metastases; migration

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; MMP9 PROTEIN, HUMAN; NOS2 PROTEIN, HUMAN; TUMOR PROTEIN;

ARTICLE; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE INTERACTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CBA MOUSE; CELL MOTION; COLORECTAL TUMOR; DRUG EFFECTS; LIVER TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL CULTURE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELL MOVEMENT; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICE, INBRED CBA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NITRIC OXIDE SYNTHASE TYPE II; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; TUMOR CELLS, CULTURED;

EID: 85002252462     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13307     Document Type: Article

References (43)

1. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control 2006; 13: 32–41.
2. Koh SL, Ager EI, Christophi C. Liver regeneration and tumour stimulation: implications of the renin-angiotensin system. Liver Int. 2010; 30: 1414–26.
3. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010; 10: 134.
4. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J. Gastroenterol. Hepatol. 2007; 22: 577–84.
5. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem. Biophys. Res. Commun. 2002; 294: 441–7.
6. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J. Clin. Invest. 1995; 95: 651–7.
7. Bates RC, Pursell BM, Mercurio AM. Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs 2007; 185: 29–39.
8. Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann. Oncol. 2007; 18: 1605–19.
9. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006; 6: 521–34.
10. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin. Cancer Res. 2005; 11: 5390–5.
11. Whitehead RH, Macrae FA, St John DJ, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl. Cancer Inst. 1985; 74: 759–65.
12. Dy DY, Whitehead RH, Morris DL. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res. 1992; 52: 917–23.
13. Kuruppu D, Christophi C, Bertram JF, O'Brien PE. Characterization of an animal model of hepatic metastasis. J. Gastroenterol. Hepatol. 1996; 11: 26–32.
14. Leenen FH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 2001; 37: 981–4.
15. Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 2005; 46: 732–7.
16. Hirano T, Ran J, Adachi M. Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. J. Hypertens. 2006; 24: 103–8.
17. Kucerova D, Zelezna B, Sloncova E, Sovova V. Angiotensin II receptors on colorectal carcinoma cells. Int. J. Mol. Med. 1998; 2: 593–5.
18. Egami K, Murohara T, Shimada T et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003; 112: 67–75.
19. Suganuma T, Ino K, Shibata K et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005; 11: 2686–94.
20. Kosaka T, Miyajima A, Takayama E et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007; 67: 41–9.
21. Benndorf R, Boger RH, Ergun S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ. Res. 2003; 93: 438–47.
22. Nadal JA, Scicli GM, Carbini LA, Nussbaum JJ, Scicli AG. Angiotensin II and retinal pericytes migration. Biochem. Biophys. Res. Commun. 1999; 266: 382–5.
23. Takeda H, Katagata Y, Hozumi Y, Kondo S. Effects of angiotensin II receptor signaling during skin wound healing. Am. J. Pathol. 2004; 165: 1653–62.
24. Kilian P, Campbell S, Bilodeau L et al. Angiotensin II type 2 receptor stimulation increases the rate of NG108-15 cell migration via actin depolymerization. Endocrinology 2008; 149: 2923–33.
25. Puddefoot JR, Udeozo UK, Barker S, Vinson GP. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocr. Relat. Cancer 2006; 13: 895–903.
26. Xia HL, Liu BC, Zhang XL et al. Role of integrin-linked kinase in renal tubular epithelial-mesenchymal transition of mice with obstructive nephropathy. Zhonghua Bing Li Xue Za Zhi 2007; 36: 43–7.
27. Liu BC, Xia HL, Wu JN, Zhang XL, Liu DG, Gong YX. Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction. Acta Pharmacol. Sin. 2007; 28: 1810–8.
28. Chen L, Liu BC, Zhang XL, Zhang JD, Liu H, Li MX. Influence of connective tissue growth factor antisense oligonucleotide on angiotensin II-induced epithelial mesenchymal transition in HK2 cells. Acta Pharmacol. Sin. 2006; 27: 1029–36.
29. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054–7.
30. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia 2010; 12: 224–34.
31. Strutz FM. EMT and proteinuria as progression factors. Kidney Int. 2009; 75: 475–81.
32. Pino MS, Kikuchi H, Zeng M et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010; 138: 1406–17.
33. Ma LJ, Nakamura S, Whitsitt JS, Marcantoni C, Davidson JM, Fogo AB. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int. 2000; 58: 2425–36.
34. Fujiyama S, Matsubara H, Nozawa Y et al. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ. Res. 2001; 88: 22–9.
35. Vyas-Read S, Shaul PW, Yuhanna IS, Willis BC. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293: L212–21.
36. Noiri E, Peresleni T, Srivastava N et al. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. Am. J. Physiol. 1996; 270: C794–802.
37. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int. J. Cancer 1999; 81: 889–96.
38. Siegert A, Rosenberg C, Schmitt WD, Denkert C, Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. Br. J. Cancer 2002; 86: 1310–5.
39. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2002; 2: 8.
40. Leng SL, Leeding KS, Gibson PR, Bach LA. Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo. Carcinogenesis 2001; 22: 1625–31.
41. Rajesh D, Schell K, Verma AK. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol. Pharmacol. 1999; 56: 515–25.
42. Nicoud IB, Jones CM, Pierce JM et al. Warm hepatic ischemia-reperfusion promotes growth of colorectal carcinoma micrometastases in mouse liver via matrix metalloproteinase-9 induction. Cancer Res. 2007; 67: 2720–8.
43. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br. J. Cancer 2002; 86: 1876–83.